JP Morgan Chase
ZNTL icon

JP Morgan Chase’s Zentalis Pharmaceuticals ZNTL Stock Holding History

JP Morgan Chase’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Sell
113,126
-71,881
-39% -$186K ﹤0.01% 5392
2025
Q4 		$250K Sell
185,007
-538,068
-74% -$783K ﹤0.01% 5415
2025
Q3 		$1.09M Buy
723,075
+172,628
+31% +$259K ﹤0.01% 4519
2025
Q2 		$639K Sell
550,447
-196,029
-26% -$259K ﹤0.01% 4644
2025
Q1 		$1.19M Sell
746,476
-113,234
-13% -$244K ﹤0.01% 4234
2024
Q4 		$2.6M Buy
859,710
+370,511
+76% +$1.21M ﹤0.01% 3944
2024
Q3 		$1.8M Sell
489,199
-6,611
-1% -$24K ﹤0.01% 4082
2024
Q2 		$2.03M Buy
495,810
+437,189
+746% +$4.88M ﹤0.01% 3778
2024
Q1 		$924K Sell
58,621
-34,827
-37% -$479K ﹤0.01% 4405
2023
Q4 		$1.42M Sell
93,448
-8,481
-8% -$124K ﹤0.01% 4094
2023
Q3 		$2.04M Sell
101,929
-8,764
-8% -$222K ﹤0.01% 3523
2023
Q2 		$3.12M Buy
110,693
+50,092
+83% +$1.2M ﹤0.01% 3219
2023
Q1 		$1.04M Buy
60,601
+13,765
+29% +$279K ﹤0.01% 4007
2022
Q4 		$943K Buy
46,836
+4,546
+11% +$97.8K ﹤0.01% 4084
2022
Q3 		$916K Sell
42,290
-14,410
-25% -$394K ﹤0.01% 4067
2022
Q2 		$1.59M Sell
56,700
-48,879
-46% -$1.29M ﹤0.01% 3726
2022
Q1 		$4.87M Buy
105,579
+78,102
+284% +$4.21M ﹤0.01% 3026
2021
Q4 		$2.31M Buy
27,477
+2,420
+10% +$187K ﹤0.01% 3743
2021
Q3 		$1.67M Buy
25,057
+6,181
+33% +$357K ﹤0.01% 3928
2021
Q2 		$1M Buy
18,876
+4,888
+35% +$262K ﹤0.01% 4282
2021
Q1 		$607K Buy
13,988
+498
+4% +$21.4K ﹤0.01% 4562
2020
Q4 		$701K Buy
13,490
+9,193
+214% +$415K ﹤0.01% 4173
2020
Q3 		$144K Buy
4,297
+820
+24% +$28.7K ﹤0.01% 4535
2020
Q2 		$167K Buy
+3,477
New +$133K ﹤0.01% 4347

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

JP Morgan Chase's ZNTL Position: Q1 2026 in Review

JP Morgan Chase reduced its Zentalis Pharmaceuticals (ZNTL) stake by 39% in Q1 2026, selling an estimated $186K and leaving 113,126 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #5392.

JP Morgan Chase first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $4.87M in Q1 2022. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • JP Morgan Chase held 113,126 shares of Zentalis Pharmaceuticals worth $242K as of Q1 2026.
  • JP Morgan Chase sold 71,881 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $186K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5392 holding.
  • JP Morgan Chase first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Zentalis Pharmaceuticals position peaked at $4.87M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.